Audentes Therapeutics Inc (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced yesterday that it has named Mark A Meltz, JD as its new senior vice president, general counsel.

Meltz has around 20 years of leadership experience serving in various roles at global pharmaceutical and biotechnology companies and a top international law firm. He joins Audentes from PaxVax, where he managed business development, legal, compliance, and government affairs/public policy functions, and led the company's October 2018 sale to Emergent BioSolutions. Prior to joining PaxVax, Meltz worked at Biogen Idec (now Biogen), where he served as the US commercial lead lawyer for Tysabri and Tecfidera (including for its US launch), and as the lead lawyer for global medical affairs. Earlier in his career, he served as head of Legal for Novartis Vaccines for North America and Latin America (including for the US launch of Menveo). Before joining the industry, Meltz practiced law at the international law firm Bingham McCutchen LLP (now part of Morgan Lewis & Bockius LLP), where he focused on mergers and acquisitions, venture capital financing, securities regulation, and general corporate matters.

Meltz earned his Juris Doctor from Boston College Law School, Magna Cum Laude, and his Bachelor of Arts with Departmental Honors in Psychology from Yale University.